VERU INC. Accounts Receivable, Allowance for Credit Loss, Writeoff
VERU INC. (VERU) reported Accounts Receivable, Allowance for Credit Loss, Writeoff of $5.00 thousand for the 12-month period ending 2021-09-30, per its 10-K filed 2021-12-02.
Discontinued › Notes › and Others › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs · last filed 2021-12-02
- VERU INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2020-09-30 was $0.00.
- VERU INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2020-06-30 was $0.00.
- VERU INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2019-09-30 was $0.00.
- VERU INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2021 was $5.00K, a 33.33% decline from fiscal 2020.
- VERU INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2020 was $7.50K, a 145.26% increase from fiscal 2019.
- VERU INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2019 was $3.06K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Writeoff 3 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 6 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 9 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 12 month |
|---|---|---|---|---|
| 2021-09-30 | $5.00K 10-K · filed 2021-12-02 | |||
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $0.00 derived: sum of 2 quarters · filed 2021-12-02 | $7.50K 10-K · filed 2021-12-02 | |
| 2020-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-13 | $7.50K 10-Q · filed 2020-08-13 | ||
| 2020-03-31 | $7.50K 10-Q · filed 2020-05-13 | |||
| 2019-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $3.06K 10-K · filed 2020-12-10 | ||
| 2019-06-30 | $3.06K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |